MedTrace Logo

"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study

NCT06044064 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-10-24

No results posted yet for this study

Summary

To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.

Purpose: To improve the rates of early detection of pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

PROCEDURE

A blood sample for CA 19-9 (cancer detection test)

* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline. * Contrast CT abdomen - Pancreas protocol will be done at baseline. * EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you. * If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done.

Sponsors & Collaborators

  • Asian Institute of Gastroenterology, India

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2027-08-01
Completion
2027-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06044064 on ClinicalTrials.gov